ACC 2023 – Merck’s oral cholesterol lowerer shows mid-stage promise
The oral PCSK9 project MK-0616 meets its targets in phase 2, which could be bad news for Novartis.
ACC 2023 – Merck reaches for the stars
The Stellar trial of sotatercept lives up to its name, but the asset did not come cheap.
Spotlight – What's next in Nash
The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.
Altimmune aims to build Momentum in obesity
A readout in the next few weeks could put pemvidutide on course for blockbuster sales – or not.
